Global Gene Therapy for Blood Disorders Market Key Players Business Strategies Analysis Report to 2030

InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Gene Therapy for Blood Disorders Market Trends, Industry Competition Analysis, Revenue and Forecast To 2030."

Request for Sample Pages:
According to the latest research by InsightAce Analytic, the global gene therapy for blood disorders market is expected to growwith a CAGR of 28.4% during a forecast period. By region, North America dominated the market with a share of XX% in 2020.

Gene therapy technique is used to modify a person's genes to treat or cure disease. It has considerable potential to treat rare blood disorders such as sickle cell disease, hemophilia. Several biopharma companies are shifting toward the gene-editing technique, CRISPR-Cas9 as a tool for fighting rare diseases. CRISPR Therapeutics company is conducting a phase I/II trial of its CRISPR/Cas9-based gene-editing therapy, CTX001, to treat sickle cell disease in collaboration with Vertex Pharmaceuticals.

Get Free Sample Copy of Report :
https://www.insightaceanalytic.com/request-sample/1156

The high prevalence of genetic and blood disorders, increasing demand for personalized medicine, growing healthcare expenditure, rising R&D activities for developing promising gene therapies to treat blood diseases are projected to fuel the market growth in the next few years. According to the study published in the PLOS Medicine Journal, sickle cell anemia cases are estimated to increase about 30% globally by the year 2050. Hence, the rising prevalence of rare hematology disorders is the key driving factor of this market.

However, the high cost of gene therapy for blood disorders and unwanted side effects are expected to hinder the market growth during the forecast period.

Geographically, North America is estimated to account for the highest share of the market in the coming years, followed by Europe owing to the high prevalence of various blood disorders, well-established healthcare systems, and increasing R&D initiatives for developing effective gene therapies to treat rare disorders.

Request for ToC/Proposal:
Major market players operating in the gene therapy for blood disorders market include BioMarin Pharmaceutical Inc. (US), Spark Therapeutics (US), Shire (US), bluebird bio, Inc. (US), CRISPR Therapeutics (US), Medgenics (US), OrphageniX (US), Freeline Therapeutics (UK), Errant Gene Therapeutics (US), Sangamo Therapeutics (US), Sigilon Therapeutics, Inc. (US), uniQure (Netherlands), Angiocrine Bioscience (US), and Sanofi Genzyme (US) among others.

Some of the key developments in the market are as follows:
In March 2021, the FDA approved the first test of CRISPR to correct genetic defects causing sickle cell disease. This CRISPR-based therapy can directly correct the mutation in the beta-globin gene responsible for sickle cell disease. Beta-globin is the protein in the hemoglobin complex accountable for carrying oxygen throughout the body.
In December 2020, bluebird bio, Inc. (US) presented the treatment results with investigational LentiGlobin gene therapy for sickle cell disease (bb1111), at the 62nd Annual ASH Meeting. This treatment eliminated SCD-related severe vaso-occlusive events in group C of phase 1/2 HGB-206 clinical study.
In May 2018, Bioverativ Inc. (US), a Sanofi company working on rare blood disorders, and Sangamo Therapeutics, Inc. announced the U.S. FDA acceptance for Investigational New Drug (IND) application for BIVV003, a gene-edited cell therapy candidate for the sickle cell disease treatment. Bioverativ and Sangamo collaborated to develop and commercialize gene-edited cell therapies for sickle cell disease and beta-thalassemia.

Curious about this latest version of the report? Obtain Report Details @
https://www.insightaceanalytic.com/report/global-gene-therapy-for-blood-disorders-market/1156

Market Segments
Global Gene Therapy for Blood Disorders Market, by Indication, 2020-2030 (Value US$ Mn)
Sickle Cell Anemia
β-thalassemia
Hemophilia B
Hemophilia A

Global Gene Therapy for Blood Disorders Market, by Mechanism of Action, 2020-2030 (Value US$ Mn)
Gene Therapy
Gene Editing

Global Gene Therapy for Blood Disorders Market, by Region, 2020-2030 (Value US$ Mn)
North America
Europe
Asia Pacific
Latin America
Middle East & Africa

North America Gene Therapy for Blood Disorders Market, by Country, 2020-2030 (Value US$ Mn)
U.S.
Canada

Europe Gene Therapy for Blood Disorders Market, by Country, 2020-2030 (Value US$ Mn)
Germany
France
Italy
Spain
Russia
Rest of Europe

Asia Pacific Gene Therapy for Blood Disorders Market, by Country, 2020-2030 (Value US$ Mn)
India
China
Japan
South Korea
Australia & New Zealand

Latin America Gene Therapy for Blood Disorders Market, by Country, 2020-2030 (Value US$ Mn)
Brazil
Mexico
Rest of Latin America

Middle East & Africa Gene Therapy for Blood Disorders Market, by Country, 2020-2030 (Value US$ Mn)
GCC Countries
South Africa
Rest of Middle East & Africa

Why should buy this report:
To receive a comprehensive analysis of the prospects for global gene therapy for blood disorders market
To receive an industry overview and future trends in gene therapy for blood disorders market
To analyze the gene therapy for blood disorders market drivers and challenges
To get information on the gene therapy for blood disorders market value (US$ Mn) and forecast to 2030
Major investments, mergers & acquisitions in the gene therapy for blood disorders market industry

For More Information @
https://www.insightaceanalytic.com/report/global-gene-therapy-for-blood-disorders-market/1156

Contact Us:
InsightAce Analytic Pvt. Ltd.
Tel.: +1 718 593 4405
Email: info@insightaceanalytic.com
Site Visit: www.insightaceanalytic.com
Follow Us on LinkedIn @ bit.ly/2tBXsgS
Follow Us On Facebook @ bit.ly/2H9jnDZ

Corporate Office :
Office No.3050, 3rd Floor Marvel Fuego, Magarpatta Rd, Hadapsar, Pune, Maharashtra 411028

Sales Office (U.S.) :
344 Grove St Unit #967 Jersey City, NJ 07302
info@insightaceanalytic.com

info@insightaceanalytic.com
North America:
+1 551 226 6109
Asia:
+91 79 72967118

This release was published on openPR.